Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but Wall Street wants proof of a turnaround.
Topic
Zepbound
Topic
Zepbound
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…